Evidence map›Paper›PMID 38774414›Full record

ArticleFrontiers in oncology2024

Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a

Barbara Castelli, Marco Tellini, Melina Guidi, Marco Di Nicola, Laura Giunti, Anna Maria Buccoliero, Maria Luigia Censullo, Alessandro Iacono, Isacco Desideri, Lorenzo Genitori and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Barbara CastelliNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Marco TelliniNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Melina GuidiNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Marco Di NicolaNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Laura GiuntiNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Anna Maria BuccolieroPathology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Maria Luigia CensulloNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Alessandro IaconoRadiology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Isacco DesideriRadiotherapy Department, Careggi Hospital, Florence, Italy.
Lorenzo GenitoriNeurosurgery Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Iacopo SardiNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
Carla FonteNeuro-oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dabrafenib plus trametinib is a promising new therapy for patients affected by

Indexed as

BRAF inhibitorsBRAFV600Edabrafenibhigh-grade gliomaMEK inhibitorspleomorphic xanthoastrocytomatarget therapytrametinib

Identifiers

PMID38774414
PMCPMC11106409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.